Cargando…
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Autologous T cells genetically engineered to express chimeric antigen receptor (CAR) have shown promising outcomes and emerged as a new curative option for hematological malignancy, especially malignant neoplasm of B cells. Notably, when T cells are transduced with CAR constructs, composed of the an...
Autores principales: | Marofi, Faroogh, Achmad, Harun, Bokov, Dmitry, Abdelbasset, Walid Kamal, Alsadoon, Zeid, Chupradit, Supat, Suksatan, Wanich, Shariatzadeh, Siavash, Hasanpoor, Zahra, Yazdanifar, Mahboubeh, Shomali, Navid, Khiavi, Farhad Motavalli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974159/ https://www.ncbi.nlm.nih.gov/pubmed/35365241 http://dx.doi.org/10.1186/s13287-022-02819-x |
Ejemplares similares
-
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
por: Razeghian, Ehsan, et al.
Publicado: (2021) -
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
por: Budi, Hendrik Setia, et al.
Publicado: (2022) -
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges
por: Razeghian, Ehsan, et al.
Publicado: (2021) -
Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy
por: Razeghian, Ehsan, et al.
Publicado: (2021)